COLLEGIUM PHARMACEUTICAL, INC (COLL)

Insider Trading Filed: 2026-05-15

Director Nancy Lurker sold 4,500 shares of COLL on 05/13/2026 at a weighted average price of $35.97, generating approximately $161,860 in proceeds, reducing her beneficial ownership to 18,017 shares.
The sale was executed across multiple transactions with prices ranging from $35.55 to $36.50, indicating an orderly liquidation rather than a panic sale at a narrow price band.
As a director selling a material portion of shares (approximately 20% reduction in her position), this insider transaction suggests either portfolio rebalancing or reduced conviction in near-term stock appreciation at current levels.

Current Report Filed: 2026-05-15

All eight director nominees were successfully elected with substantial shareholder support, with Michael Donovan receiving the highest vote count (27.38M for votes, 99.87% approval rate), indicating strong board confidence.
Executive compensation received advisory shareholder approval with 96.0% voting in favor (26.31M for votes), demonstrating shareholder alignment with management's pay practices despite 1.10M opposing votes.
Deloitte & Touche LLP was ratified as the independent auditor with overwhelming approval at 99.1% (28.95M for votes) and zero broker non-votes, reflecting consistent audit firm confidence.
Voting participation was strong at 90.1% of shares outstanding (29.21M of 32.41M shares), suggesting healthy shareholder engagement in corporate governance matters.

Insider Trading Filed: 2026-05-13

Director Garen G. Bohlin executed a significant net sell transaction on 05/11/2026, selling 8,700 shares at a weighted average price of $37.18-$37.43 while simultaneously acquiring 8,700 shares at $16.49, representing a complex hedging or option exercise strategy rather than a pure directional bet.
The sale at $37.18+ represents a substantial premium over the acquisition price of $16.49, suggesting Bohlin may be realizing gains on stock option exercises or executing a pre-planned trading strategy to diversify holdings.
Bohlin's beneficial ownership decreased from 70,959 to 62,259 shares (net reduction of 8,700 shares or 12.3%), indicating insider selling pressure that could signal reduced confidence in near-term stock appreciation or portfolio rebalancing.
The stock option exercised (8,700 shares at $16.49 strike, expiring 06/09/2026) was fully vested and exercisable, suggesting this was a deliberate tactical execution rather than an automatic equity grant, with shares immediately sold at significantly higher prices.

Current Report Filed: 2026-05-12

Collegium completed a major $650 million acquisition of AZSTARYS (a CNS stimulant for ADHD treatment) funded by $350 million cash and $300 million from delayed draw term loan, with up to $135 million in additional milestone-based payments.
Leadership departures of Chief Commercial Officer Scott Dreyer (effective August 30, 2026) and Chief Medical Officer Thomas Smith signal potential integration challenges or strategic repositioning following the significant acquisition.
The company adopted a 2026 Inducement Plan for 325,000 shares to attract new employees, likely reflecting staffing needs to integrate the acquired AZSTARYS business and support commercial expansion.
Financial statements and pro forma information for the acquisition will be filed within 71 days, leaving investors awaiting detailed analysis of the acquisition's financial impact and integration plans.

Quarterly Report Filed: 2026-05-07

The filing contains multiple acquisition-related activities including the AZSTARYS acquisition completed on March 19, 2026, and the ongoing integration of the Ironshore acquisition from September 2024, indicating active portfolio expansion strategy.
Revenue recognition includes multiple branded pharmaceutical products (Belbuca, Xtampza ER, Jornay PM, Nucynta formulations, Symproic) with detailed allowance tracking for rebates, incentives, and chargebacks, suggesting complex commercialization and significant customer-managed pricing pressures.
The company maintains multiple license agreements (Grunenthal and Shionogi) with corresponding obligations and fair value considerations across different fair value measurement levels, indicating dependency on licensed assets for core revenue generation.
Equity compensation activity across employee stock options, RSUs, performance shares, and an employee stock purchase plan suggests active talent retention efforts, though details on option pricing and vesting schedules would require full document review for dilution impact assessment.

Current Report Filed: 2026-05-07

Collegium Pharmaceutical announced Q1 2026 financial results on May 7, 2026, with earnings presentation accompanying the earnings release, indicating normal quarterly reporting cycle.
The filing is a routine 8-K for earnings disclosure under Item 2.02 and includes supplemental presentation materials under Item 7.01 Regulation FD Disclosure, typical for pharmaceutical company quarterly updates.
Signed by CFO Colleen Tupper, confirming proper corporate authorization and that financial results have been prepared and disclosed in accordance with SEC requirements.
No material events, significant guidance changes, strategic transactions, or leadership changes are indicated in this filing - it appears to be a standard quarterly earnings announcement.

Current Report Filed: 2026-04-07

Collegium Pharmaceutical nominated Michael Donovan, a former EY audit partner with extensive life sciences industry experience, to stand for election to the board at the 2026 Annual Meeting.
John Fallon, a current board member since 2016, will not stand for re-election and will retire from the board at the 2026 Annual Meeting.
The board refreshment and succession planning does not appear to be due to any disagreement with the company, signaling an orderly transition.

Insider Trading Filed: 2026-04-03

The reporting person, David Dieter, who is the EVP & General Counsel of Collegium Pharmaceutical, Inc., disposed of 8,840 shares of the company's common stock to satisfy applicable withholding taxes upon the vesting of restricted stock units.
The transaction was executed on March 17, 2026, and Dieter still holds 68,231 shares of the company's common stock directly.
Insider transactions like this can provide insights into management's views on the company's stock and their confidence in its future performance.

Insider Trading Filed: 2026-03-20

The reporting person, Dieter David, sold 13,976 shares of the company's common stock on March 18, 2026, reducing their total beneficial ownership to 77,071 shares.
The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 5, 2025.
The shares were sold at a weighted average price of $34.9241 per share, in multiple transactions ranging from $34.74 to $35.39 per share.

Annual Report Filed: 2026-02-26

The company reported a significant increase in revenue for fiscal year 2025, indicating strong growth in their core business.
Collegium Pharmaceutical faced several legal challenges during the year, including patent disputes and stockholder lawsuits, which could pose risks to their future operations.
The company made a strategic acquisition of Ironshore, which could expand their product portfolio and market presence, but also introduces integration and execution risks.

Current Report Filed: 2026-02-26